文 献 8）Esposito A, Criscitiello C, Gelao L, Pravettoni G, Locatelli M, Minchella I, et al. Mechanisms of anorexia-cachexia syndrome and rational for treatment with selective ghrelin receptor agonist. Cancer Treat Rev 2015; 41(9): 793-7. 9）Katakami N, Uchino J, Yokoyama T, Naito T, Kondo M, Yamada K, et al. Anamorelin (ONO-7643) for the treatment of patients with non-small cell lung cancer and cachexia: Results from a randomized, double-blind, placebo-controlled, multicenter study of Japanese patients (ONO-7643-04). Cancer 2018; 124(3): 606-16.10）Hamauchi S, Furuse J, Takano T, Munemoto Y, Furuya K, Baba H, et al. A multicenter, open-label, single-arm study of anamorelin (ONO-7643) in advanced gastrointestinal cancer patients with cancer cachexia. Cancer 2019; 125(23): 4294-302.11）Enomoto Y, Nakamura Y, Satake Y, Sumikawa H, Johkoh T, Colby TV, et al. Clinical diagnosis of idiopathic pleuroparenchymal fibroelastosis: A retrospective multicenter study. Respir Med 2017; 133: 1-5.12）Kitahara S, Abe M, Kono C, Sakuma N, Ishii D, Kawasaki T, et al. Prognostic impact of the cross-sectional area of the erector spinae muscle i n p a t i e n t s w i t h p l e u r o p a r e n c h y m a l fibroelastosis. Sci Rep 2023; 13(1): 17289.13）アナモレリン塩酸塩錠（エドルミズ ®）添付文書. 小 野 薬 品 工 業 株 式 会 社. 2025 年 3 月 改 訂. [https://pins.japic.or.jp/pdf/newPINS/00069223.pdf (accessed 2025-10-10)]型肺線維症. 呼吸 1992; 11(6): 693-99.特発性上葉優位型肺線維症（iPPFE）に対するアナモレリンの有効性と安全性の検討 1）網谷良一、新実彰男、久世文幸. 特発性上葉限局 2）Travis WD, Costabel U, Hansell DM, King TE Jr, Lynch DA, Nicholson AG, et al. ATS/ERS Committee on Idiopathic Interstitial Pneumonias. An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2013; 188(6): 733-48. 3）Nakamura Y, Mori K, Enomoto Y, Kono M, Sumikawa H, Johkoh T, et al. Prognostic and clinical value of cluster analysis in idiopathic pleuroparenchymal fibroelastosis phenotypes. J Clin Med 2021; 10(7): 1498. 4）厚生労働省. 指定難病の概要、診断基準等. 85 特 発 性 間 質 性 肺 炎 . [https://www.mhlw.go.jp/content/10905000/001173504.pdf (accessed 2025-10-1)] 5）Suzuki Y. Idiopathic pleuroparenchymal fibroelastosis: A review of the previous literature and current knowledge. Respir Investig 2025; 63: 127-37. 6）Kinoshita Y, Miyamura T, Ikeda T, Ueda Y, Yoshida Y, Kushima H, et al. Limited efficacy of nintedanib for idiopathic pleuroparenchymal fibroelastosis. Respir Investig 2022; 60(4): 562-9. 7）Kono M, Saito T, Tsunoda T, Ikeda S, Arano T, Watanuki M, et al. Prognostic significance of body mass index and weight loss in patients with idiopathic pleuroparenchymal fibroelastosis. Sarcoidosis Vasc Diffuse Lung Dis 2024; 41(2): e202426.51
元のページ ../index.html#65